IGC Pharma, Inc. (IGC)

Price$0.29

Value ScoreD

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-23.42%

Price vs S&P 500 (4W)-18.71%

VGM Score36.74

Market Capitalization$28.92M

All Metrics

Book Value / Share (Quarterly)$0.06

P/TBV (Annual)11.25x

Revenue Growth (3Y)-1.52%

Cash Flow / Share (Quarterly)$-0.07

Price vs S&P 500 (YTD)-8.27%

Gross Margin (TTM)29.68%

Net Profit Margin (TTM)-552.11%

EPS (TTM)$-0.07

10-Day Avg Trading Volume0.81M

EPS Excl Extra (TTM)$-0.07

Revenue Growth (5Y)-0.70%

EPS (Annual)$-0.05

ROI (Annual)-54.86%

Gross Margin (Annual)34.18%

Net Profit Margin (5Y Avg)-1404.75%

Cash / Share (Quarterly)$0.00

Revenue Growth QoQ (YoY)-3.94%

ROA (Last FY)-42.69%

Revenue Growth TTM (YoY)-6.69%

EBITD / Share (TTM)$-0.11

ROE (5Y Avg)-97.20%

Operating Margin (TTM)-860.29%

Cash Flow / Share (Annual)$-0.06

P/B Ratio4.72x

P/B Ratio (Quarterly)3.99x

Net Income / Employee (Annual)$-59,200

EV / Revenue (TTM)24.98x

Net Interest Coverage (TTM)-58.67x

ROA (TTM)-71.60%

EV / EBITDA (TTM)9.32x

EPS Incl Extra (Annual)$-0.05

Current Ratio (Annual)0.83x

Quick Ratio (Quarterly)0.12x

3-Month Avg Trading Volume0.91M

52-Week Price Return-11.30%

Revenue / Employee (TTM)$16,900

Tangible BV / Share (Quarterly)$0.01

P/S Ratio (Annual)33.28x

Asset Turnover (Annual)0.09x

52-Week High$0.50

Operating Margin (5Y Avg)-1519.14%

EPS Excl Extra (Annual)$-0.05

CapEx CAGR (5Y)-16.30%

Tangible BV CAGR (5Y)-40.97%

26-Week Price Return-7.49%

Quick Ratio (Annual)0.47x

13-Week Price Return1.44%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)0.40x

Enterprise Value$29.63M

Revenue / Share Growth (5Y)-14.46%

Asset Turnover (TTM)0.13x

Book Value / Share Growth (5Y)-35.25%

Revenue / Employee (Annual)$12,400

Inventory Turnover (Annual)0.45x

Pretax Margin (Annual)-477.10%

Cash / Share (Annual)$0.01

3-Month Return Std Dev50.50%

Gross Margin (5Y Avg)46.65%

Net Income / Employee (TTM)$-93,500

ROE (Last FY)-55.85%

Net Interest Coverage (Annual)-7.57x

EPS Basic Excl Extra (Annual)$-0.05

P/FCF (TTM)107.10x

Receivables Turnover (TTM)33.41x

Total Debt / Equity (Quarterly)0.15x

EPS Incl Extra (TTM)$-0.07

Receivables Turnover (Annual)34.82x

ROI (TTM)-90.20%

P/S Ratio (TTM)24.38x

Pretax Margin (5Y Avg)-1404.75%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$0.02

Price vs S&P 500 (52W)-39.50%

Year-to-Date Return2.67%

5-Day Price Return0.31%

EPS Normalized (Annual)$-0.05

ROA (5Y Avg)-75.67%

Net Profit Margin (Annual)-477.10%

Month-to-Date Return-9.61%

Cash Flow / Share (TTM)$-0.19

EBITD / Share (Annual)$-0.08

Operating Margin (Annual)-891.25%

LT Debt / Equity (Annual)0.02x

ROI (5Y Avg)-95.63%

LT Debt / Equity (Quarterly)0.03x

EPS Basic Excl Extra (TTM)$-0.07

P/TBV (Quarterly)28.63x

P/B Ratio (Annual)3.52x

Inventory Turnover (TTM)0.83x

Pretax Margin (TTM)-552.11%

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)-8.31%

Beta0.46x

Revenue / Share (TTM)$0.01

ROE (TTM)-94.51%

52-Week Low$0.24

vGradeD

gGradeD

mGradeC

vgmGradeD

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
IGCIGC Pharma, Inc.	D	D	C	$0.29
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

IGC Pharma develops cannabinoid-based therapeutics for neurological and pain disorders. The company's Alzheimer's disease program includes four investigational candidates (IGC-AD1, IGC-M3, IGC-1C, and TGR-63) that have demonstrated preclinical potential to reduce amyloid plaques and tau tangles. Additional pipeline programs target period cramps, premenstrual syndrome, and chronic pain.